share_log

AstraZeneca | 6-K: Voydeya Recommended for Approval in the Eu by CHMP as Add-On Treatment to Ravulizumab or Eculizumab for Adults with PNH Who Have Residual Haemolytic Anaemia

SEC announcement ·  Feb 26 06:25
Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more